Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer

被引：12

作者：

Atmaca, Akin ^{[1
]}

Pauligk, Claudia ^{[1
]}

Steinmetz, Kristina ^{[1
]}

Altmannsberger, Hans-Michael ^{[2
]}

Jaeger, Elke ^{[1
]}

Al-Batran, Salah-Eddin ^{[1
]}

机构：

[1] Krankenhaus NW Frankfurt, Dept Hematol & Oncol, DE-60488 Frankfurt, Germany

[2] Krankenhaus NW Frankfurt, Inst Pathol, DE-60488 Frankfurt, Germany

来源：

ONCOLOGY | 2011年 / 80卷 / 1-2期

关键词：

p-MAPK; Erk1; Erk2; Gastric cancer; Survival; Prognostic parameter; ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE; PHASE-III; FLUOROURACIL; OXALIPLATIN; ADENOCARCINOMA; LEUCOVORIN; CISPLATIN; DOCETAXEL; THERAPY; TRIAL;

D O I：

10.1159/000329063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：130 / 134

页数：5

共 15 条

[11] Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma [J].

Muller, W ;

Schneiders, A ;

Meier, S ;

Hommel, G ;

Gabbert, HE .

BRITISH JOURNAL OF CANCER, 1996, 74 (05) :759-765

[12] Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma [J].

Pelloski, Christopher E. ;

Lin, E. ;

Zhang, Li ;

Yung, W. K. Alfred ;

Colman, Howard ;

Liu, Juinn-Lin ;

Woo, Shaio Y. ;

Heimberger, Amy B. ;

Suki, Dima ;

Prados, Michael ;

Chang, Susan ;

Barker, Fredrick G., III ;

Fuller, Gregory N. ;

Aldape, Kenneth D. .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3935-3941

[13] Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors [J].

Qi, Jie ;

McTigue, Michele A. ;

Rogers, Andrew ;

Lifshits, Eugene ;

Christensen, James G. ;

Jaenne, Pasi A. ;

Engelman, Jeffrey A. .

CANCER RESEARCH, 2011, 71 (03) :1081-1091

[14] Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells [J].

Shigematsu, Hideo ;

Yoshida, Kazuhiro ;

Sanada, Yuichi ;

Osada, Shinnji ;

Takahashi, Takao ;

Wada, Yoshiyuki ;

Konishi, Kazuo ;

Okada, Morihito ;

Fukushima, Masakazu .

INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (11) :2716-2725

[15] Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group [J].

Van Cutsem, Eric ;

Moiseyenko, Vladimir M. ;

Tjulandin, Sergei ;

Majlis, Alejandro ;

Constenla, Manuel ;

Boni, Corrado ;

Rodrigues, Adriano ;

Fodor, Miguel ;

Chao, Yee ;

Voznyi, Edouard ;

Risse, Marie-Laure ;

Ajani, Jaffer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :4991-4997

← 1 2 →